Page last updated: 2024-08-26

fulvestrant and Adverse Drug Event

fulvestrant has been researched along with Adverse Drug Event in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
D'Assoro, A; Goetz, MP; Haddad, TC; Ingle, JN; Liu, MC; Opyrchal, M; Peethambaram, P; Suman, V	1
André, F; Bartlett, CH; Bhattacharyya, H; Cristofanilli, M; Harbeck, N; Iwata, H; Iyer, S; Loi, S; Loibl, S; Puyana Theall, K; Ro, J; Turner, N; Verma, S	1

Trials

2 trial(s) available for fulvestrant and Adverse Drug Event

Article	Year
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast cancer research and treatment, 2018, Volume: 168, Issue:3 Topics: Aged; Antineoplastic Agents, Hormonal; Azepines; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Pyrimidines	2018
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Patient Reported Outcome Measures; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen	2016

Article

Year

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.

Breast cancer research and treatment, 2018, Volume: 168, Issue:3

Topics: Aged; Antineoplastic Agents, Hormonal; Azepines; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Pyrimidines

2018

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Patient Reported Outcome Measures; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen

2016

Other Studies

2 other study(ies) available for fulvestrant and Adverse Drug Event

Article	Year
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, 2011, Volume: 7, Issue:12 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology, 2011, Volume: 7, Issue:12

Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests

2011

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013